MAP4 and cancer: Not only does this study demonstrate a model of agonist-stimulated PI3K-Akt on endosomes that is supported by extensive data, but it also highlights the potential of the MAP4-PI3K interaction as a therapeutic target as PI3K hyperactivation occurs frequently in many cancers and MAP4 is overexpressed in diverse tumors [123,124].